Leerink downgraded Deciphera to Market Perform from Outperform with a price target of $25.60, down from $34, after Japanese pharma company Ono Pharmaceutical announced it would acquire Deciphera in an all-cash transaction for $25.60 per share. The firm notes that the boards of directors of both companies unanimously approved the transaction and it sees little risk of deal closure.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.